Checkpoint inhibitors ( 2016)
Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, USA provides an overview of monoclonal antibodies and checkpoint inhbitors for multiple myeloma at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) held in Paris, France. Currently, two antibodies are approved

Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, and President of the European Society for Blood and Marrow Transplantation (EBMT), talks about the a symposium hosted at the 2016 Annual Meeting of EBMT, held in Valencia, Spain, focusing on the role of proteosome inhibitors in multiple

Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides advice on how to treat multiple myeloma (MM). For patients younger than 75, autologous transplantation remains the standard of care and Dr Palumbo also suggests a three-drug combination induction therapy.

HDAC Inhibition

Jatin J. Shah, MD, and Andrew Spencer, MD, discuss the evidence for the use of histone deacetylase inhibitors, such as panobinostat, in multiple myeloma